An official website of the United States government
Continue to develop animal models with higher predictive validity for use in preclinical drug development and to accelerate the discovery of translationally relevant disease mechanisms and treatment strategies.
2024 PAR-18-596: Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01) NOT-AG-18-001 (#9): Neuropsychiatric Symptoms in Alzheimer's Disease (NPS-AD) RFA-MH-19-510: Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01) RFA MH-19-511: Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21) RFA- AG-21-003: New Unconventional Animal Models of Alzheimer’s Disease (R24) 4.C Achieved Continue to develop animal models with higher predictive validity for use in preclinical drug development… DN 2018 AD Summit: 2O, 2N, 3F and 3G 2021 AD Summit: 2.B News: Animal model mimics earliest stages of Alzheimer's in humans Translational Tools, Infrastructure, and Capabilities MODEL-AD MODEL-AD Resources Tau-associated Pathological Changes in Reward Networks For the Prediction of Neuropsychiatric Symptoms in Alzheimer’s Disease MARMO-AD: Generation, Characterization, and Validation of Marmoset Models of Alzheimer's Disease Select projects funded in FY21 MARMO-AD: Establishing marmoset models of Alzheimer’s Disease to identify emerging phenotypes and illuminate mechanisms underlying pathogenesis MARMO-AD Resources
Expand the existing open-source/open-science translational infrastructure for next generation AD animal models by developing:
- New transgenic mouse models with humanized immune systems expressing AD risk related human genes for use in preclinical drug development and to gain a better understanding of the role of the immune system in risk and progression of AD/ADRD.
- Non-human primate models (such as marmosets genetically engineered with Alzheimer’s disease risk variants) and other non-human primate models for use in comparative aging biology and integrative physiology studies of AD and to bridge the translational gap between rodents and humans
- Animal models for the neuropsychiatric symptoms of AD.
Summary of Key Accomplishments
NIA's New Un-conventional Animal Models of Alzheimer’s Disease is an initiative to encourage research aimed at developing and characterizing innovative non-rodent mammalian models of late-onset (sporadic) AD.
These new models are expected to recapitulate molecular, cellular, neuropathological, behavioral, and/or cognitive features of late-onset AD. Seven highly cross-disciplinary projects have been initiated. One of the funded grants is supporting the Dog Aging Project, a consortium aimed at understanding the biological aging process, including age-related cognitive changes and dementia, in companion dogs through large-scale longitudinal study and clinical evaluation.
The key accomplishments summary is current as of July 2022.